Brinzolamide/timolol: In open-angle glaucoma and ocular hypertension

Drugs and Aging

Volumn 26, Issue 5, 2009, Pages 437-446

  Croxtall, Jamie D ^a,b   Scott, Lesley J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; AZARGA; BRINZOLAMIDE; BRINZOLAMIDE PLUS TIMOLOL; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; TIMOLOL; UNCLASSIFIED DRUG;

BLOOD PRESSURE; BLURRED VISION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EYE IRRITATION; EYE PAIN; HUMAN; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LUNG DISEASE; MONOTHERAPY; NAUSEA; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PUNCTATE KERATITIS; REVIEW; SIDE EFFECT; SUSPENSION; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; CARBONIC ANHYDRASE INHIBITORS; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; SULFONAMIDES; THIAZINES; TIMOLOL;

EID: 68149114500     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-200926050-00007     Document Type: Review

References (32)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82 (11): 844-51
2. Glaucoma Research Foundation. African-Americans and glaucoma [online]. Available from URL: http://www.glaucoma. org/learn/africanamerican.php [Accessed 2009 Feb 12]
3. Muñoz B, West S, Rubin G, et al. Causes of blindness and visual impairment in a population of older Americans. Arch Ophthalmol 2000; 118 (6): 819-25
4. Goldberg L. Clinical guidelines for the treatment of glaucoma. Manag Care 2002; 11 (11): 16-24
5. Fechtner RD, Khouri AS. Evolving global risk assessment of ocular hypertension to glaucoma. Curr Opin Ophthalmol 2007; 18 (2): 104-9
6. Glaucoma Research Foundation. Are you at risk for glaucoma? [online]. Available from URL: http://www.glaucoma. org/learn/are-you-at-risk.php [Accessed 2009 Feb 12]
7. The Eye Digest: University of Illinois Eye & Ear Infirmary. Glaucoma causes optic nerve cupping (atrophy) and vision loss [online]. Available from URL: http://www.agingeye.net/ glaucoma/glaucomainformation.php [Accessed 2009 Feb 13]
8. Foster A, Johnson G. Magnitude and causes of blindness in the developing world. Int Ophthalmol 1990; 14 (3): 135-40
9. Klaver C, Wolfs R, Vingerling J, et al. Age-specific prevalence and causes of blindness in an older population. Arch Ophthalmol 1998; 116 (5): 653-8
10. Forsman E, Kivela T, Vesti E. Lifetime visual disability in open-angle glaucoma and ocular hypertension. J Glaucoma 2007; 16 (3): 313-9
11. The Royal College of Ophthalmologists. A national research strategy for ophthalmology (March 2002) [online]. Available from URL: http://www.rcophth.ac. uk/docs/publications/ published-guidelines/EyeResearchFinal.pdf [Accessed 2009 Feb 5]
12. European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. Savona, Italy: Dogma, 2008
13. Japan Glaucoma Society. Guidelines for glaucoma [online]. Available from URL: http://www.ryokunaisho.jp/english/ Guidelines-for-Glaucoma.pdf [Accessed 2009 Feb 13]
14. Kass M, Heuer D, Higginbotham E, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays prevents the onset of open-angle glaucoma. Arch Ophthalmol 2002; 120 (6): 701-13
15. Geringer C, Imami N. Medical management of glaucoma. Int Ophthamol Clin 2008; 48 (4): 115-41
16. International Council of Ophthalmology. Primary open-angle glaucoma (initial evaluation) [online]. Available from URL: http://www.icoph.org/guide/ guidepri.html [Accessed 2009 Feb 13]
17. Fechtner R, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophtahalmol 2004; 15 (2): 132-5
18. Cvetkovic RS, Perry CM. Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 2003; 20 (12): 919-47
19. Iester M. Brinzolamide. Expert Opin. Pharmacother 2008; 9 (4): 653-62
20. DeSantis L. Preclinical overview of brinzolamide. Surv Opthalmol 2000; 44 (Suppl. 2): S119-29
21. Heel R, Brogden R, Speight T, et al. Timolol: a review of its therapeutic efficacy in the topical treatment of glaucoma. Drugs 1979; 17 (1): 38-55
22. Han JA, Frishman WH, Wu Sun S, et al. Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev 2008;16(2): 95-108
23. March W, Ochsner K. The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension. Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol 2000; 129 (2): 136-43
24. European Agency for the Evaluation of Medicinal Products. Brinzolamide/timolol: summary of product characteristics [online]. Available from URL: http://www.emea.europa. eu/humandocs/PDFs/EPAR/azarga/H-960-PI-en.pdf [Accessed 2009 Feb 2]
25. Kaup M, Plange N, Niegel M, et al. Effects of brinzolamide on ocular haemodynamics in healthy volunteers. Br J Ophthalmol 2004; 88 (2): 257-62
26. Izzotti A, Sacca S, Di Marco B, et al. Antioxidant activity of timolol on endothelial cells and its relevance for glaucoma course. Eye 2008; 22 (3): 445-53
27. Kiland J, Gabelt B, Kaufman P. Studies on the mechanism of action of timolol and the effects and redirection of aqueous flow on outflow facility. Exp Eye Res 2004; 78 (3): 639-51
28. Korte J, Kaila T, Saari K, et al. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 2002; 240 (6): 430-5
29. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2009; 18 (4): 293-300
30. Kaback M, Scoper SV, Arzeno G, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1 % and timolol 0.5%. Ophthalmology 2008; 115 (10): 1728-34
31. Vold SD, Evans RM, Stewart RH, et al. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2008; 24 (6): 601-5
32. Mundorf TK, Rauchman SH, Williams RD, et al. A patient preference comparison of Azarga™ (brinzolamide/timolol fixed combination) vs Cosopt® (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2008; 2 (3): 623-8